Social Media Use Becomes Less Unclear With Off-Label Guidance

As social media technology grows, so do the questions regarding what information companies can put up on sites, and where they can put it. A new FDA draft guidance for drug- and devicemakers offers advice on unsolicited off-label questions via social media.

But many questions remain for manufacturers who want to use social media tools to advertise their products.

One bright spot: The FDA urged companies responding to unsolicited off-label info requests to keep conversations private and narrow.

While the swift embrace of social media has made it easier for consumers and healthcare providers to talk about treatments, it also has created potential new compliance pitfalls for companies that need to stay within the FDA’s fair balance boundaries for benefit-risk information. There still isn’t a bright line for the FDA’s disclosure requirements for promotional labeling and advertising. Figuring out what to do can cause quite a headache — and risk an untitled letter.

FDAnews has the solution here and now: Social Media Strategies for Drug and Device Companies is a report that answers your questions about how the FDA is applying its regulations to social media marketing and advertising and how to troubleshoot risks and challenges most effectively. In addition to parsing out the latest guidance for off-label communications, this report will help keep your pharma marketers up to date with current requirements and how to get your message out with an ever-changing technology.

Don’t let the next wave of technology drown you, click here to order your copy of Social Media Strategies for Drug and Device Companies today!